(Q42722817)

5 November 2017

title

CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects (English)

1 reference

5 November 2017

1 reference

K Nakamura

1

1 reference

5 November 2017

K Obayashi

2

1 reference

5 November 2017

T Araki

3

1 reference

5 November 2017

T Aomori

4

1 reference

5 November 2017

Y Fujita

5

1 reference

5 November 2017

Y Okada

6

1 reference

5 November 2017

M Kurabayashi

7

1 reference

5 November 2017

A Hasegawa

8

1 reference

5 November 2017

S Ohmori

9

1 reference

5 November 2017

T Nakamura

10

1 reference

5 November 2017

K Yamamoto

11

1 reference

5 November 2017

publication date

16 December 2011

1 reference

Journal of Clinical Pharmacy and Therapeutics

5 November 2017

published in

1 reference

5 November 2017

volume

37

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

481-485

1 reference

Human P450 metabolism of warfarin

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genetic and clinical factors relating to warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genetic and clinical predictors of warfarin dose requirements in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Genetic determinants of warfarin dosing in the Han-Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

Application of Akaike information criterion to evaluate warfarin dosing algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01317.X

10.1111/J.1365-2710.2011.01317.X

21 January 2018

Identifiers

DOI

1 reference

5 November 2017

1 reference